Literaturhinweise

In der Diskussion:
Können die Alzheimer- und Parkinson-Krankheit durch selbstreplizierende Proteinpartikel übertragen werden?

1) *Minati L, Edginton T, Bruzzone MG, Giaccone G*
(2009) Current concepts in Alzheimer's disease: a multidisciplinary review.
Am J Alzheimers Dis Other Demen ***24:****95-121.*

2) *Iqbal K, Liu F, Gong CX, Grundke-Iqbal I*
(2010) Tau in Alzheimer disease and related tauopathies.
Curr Alzheimer Res ***7:****656-664.*

3) *Davie CA*
(2008) A review of Parkinson's disease.
Br Med Bull ***86:****109-127.*

4) *Parchi P, Saverioni D*
(2012) Molecular pathology, classification, and diagnosis of sporadic human prion disease variants.
Folia Neuropathol ***50:****20-45.*

5) *Sikorska B, Knight R, Ironside JW, Liberski PP*
(2012) Creutzfeldt-Jakob disease.
Adv Exp Med Biol ***724:****76-90.*

6) *Prusiner SB (1982)*
Novel proteinaceous infectious particles cause scrapie.
Science ***216:****136-144.*

7) *Prusiner SB*
(1998) Prions.
Proc Natl Acad Sci USA ***95:****13363-13383.*

8) *Chiti F, Dobson CM*
(2006) Protein misfolding, functional amyloid, and human disease.
Annu Rev Biochem ***75:****333-366.*

9) *Brown P, Cervenakova L*
(2005) A prion lexicon (out of control).
Lancet ***365:****122.*

10) *Come JH, Fraser PE, Lansbury PT*
(1993) A kinetic model for amyloid formation in the prion diseases: importance of seeding.
Proc Natl Acad Sci USA ***90:****5959-5963.*

11) *Soto C*
(2011) Prion hypothesis: the end of the controversy?
Trends Biochem Sci ***36:****151-158.*

12) *Moreno JA, Radford H, Peretti D, et al.*
(2012) Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration.
Nature ***485:****507-511.*

13) *Brown P, Brandel JP, Sato T, et al.*
(2012) Iatrogenic Creutzfeldt-Jakob disease, final assessment.
Emerg Infect Dis ***18:****901-907.*

14) *Beekes M*
(2010) Die variante Creutzfeldt-Jakob-Krankheit (vCJK). Epidemiologie und Schutzmaßnahmen gegen eine Übertragung von Mensch zu Mensch.
*BundesgesundheitsblGesundheitsforschGesundheitsschutz **53:**597-606.*

15) *Peden A, McCardle L, Head MW, et al.*
(2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.
*Haemophilia **16:**296-304*

16) *Task Force vCJK*
(2002) Die Variante der Creutzfeldt-Jakob-Krankheit (vCJK). Epidemiologie, Erkennung, Diagnostik und Prävention unter besonderer Berücksichtigung der Risikominimierung einer iatrogenen Übertragung durch Medizinprodukte, insbesondere chirurgische Instrumente - Abschlussbericht der Task Force vCJK zu diesem Thema.
*BundesgesundheitsblGesundheitsforschGesundheitsschutz **45:**376-394.*

17) *Arbeitsgruppe "Gesamtstrategie Blutversorgung angesichts vCJK"*
(2006) Bericht der Arbeitsgruppe "Gesamtstrategie Blutversorgung angesichts vCJK". http://www.pei.de/SharedDocs/Downloads/blut/gesamtstrategie/gesamtstrategie-bericht-2006.pdf?__blob=publicationFile&v=1 (Letzter Zugriff: 28.02.2013).

18) *Beekes M, McBride PA*
(2007) The spread of prions through the body in naturally acquired transmissbile spongiform encephalopathies.
*FEBS J **264:**588-605.*

19) *Brundin P, Melki R, Kopito R*
(2010) Prion-like transmission of protein aggregates in neurodegenerative diseases.
*Nat Rev Mol Cell Biol **11:**301-307.*

20) *Lee SJ, Lim HS, Masliah E, Lee HJ*
(2011) Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives.
*Neurosci Res **70:**339-348.*

21) *Jucker M, Walker LC*
(2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.
*Ann Neurol **70:**532-540.*

22) *Polymenidou M, Cleveland DW*
(2011) The seeds of neurodegeneration: prion-like spreading in ALS.
*Cell **147:**498-508.*

23) *Guest WC, Silverman JM, Pokrishevsky E, O'Neill MA, Grad LI, Cashman NR*
(2011) Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.
*J Toxicol Environ Health A **74:**1433-1459.*

24) *Polymenidou M, Cleveland DW*
(2012) Prion-like spread of protein aggregates in neurodegeneration.
*J Exp Med **209:**889-893.*

25) *Arbeitskreis Blut des Bundesministeriums für Gesundheit (2012)*
Sicherheit von Blut und Blutprodukten angesichts aktueller Berichte über die Übertragbarkeit der Alzheimer-Krankheit im Tierexperiment.
http://www.rki.de/DE/Content/Kommissionen/AK_Blut/Stellungnahmen/download/stAlzheimer_Erlaeuterungen.pdf?__blob=publicationFile (Letzter Zugriff: 28.02.2013).

26) *Olanow CW, Brundin P (2013)*
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
*Mov Disord **28:**31-40.*

Literaturhinweise

27) *Walker L, Levine H, Jucker M*
(2006) Koch's postulates and infectious proteins.
Acta Neuropathol ***112:****1-4.*

28) *Kane MD, Lipinski WJ, Callahan MJ, et al.*
(2000) Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.
J Neurosci ***20:****3606-3611.*

29) *Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al.*
(2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.
Science ***313:****1781-1784.*

30) *Eisele YS, Bolmont T, Heikenwalder M, et al.*
(2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation.
Proc Natl Acad Sci U S A ***106:****12926-12931.*

31) *Eisele YS, Obermuller U, Heilbronner G, et al.*
(2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
Science ***330:****980-982.*

32) *Stöhr J, Watts JC, Mensinger ZL, et al.*
(2012) Purified and synthetic Alzheimer's amyloid beta (Abeta) prions.
Proc Natl Acad Sci U S A ***109:****11025-11030.*

33) *Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ*
(1994) Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy.
MolNeurobiol ***8:****25-39.*

34) *Maclean CJ, Baker HF, Ridley RM, Mori H*
(2000) Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (Callithrix jacchus).
J Neural Transm ***107:****799-814.*

35) *Ridley RM, Baker HF, Windle CP, Cummings RM*
(2006) Very long term studies of the seeding of beta-amyloidosis in primates.
J Neural Transm ***113:****1243-1251.*

36) *Brown P, Gibbs CJ, Jr., Rodgers-Johnson P, et al.*
(1994) Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease.
AnnNeurol ***35:****513-529.*

37) *Irwin DJ, Abrams JY, Schonberger LB, et al.*
(2013) Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone.
AMA Neurol:1-7.

38) *Caughey B, Baron GS, Chesebro B, Jeffrey M*
(2009) Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.
Annu Rev Biochem ***78:****177-204.*

39) *Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C (2011)*
De novo induction of amyloid-b deposition in vivo.
Mol Psychiatry ***17:****1347-1353.*

40) *Rosen RF, Fritz JJ, Dooyema J, et al.*
(2012) Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats.
J Neurochem ***120:****660-666.*

41) *Ashe KH, Aguzzi A*
(2013) Prions, prionoids and pathogenic proteins in Alzheimer disease.
Prion ***7:****55-59.*

42) *Soto C, Salvadores-Bersezio N, Moreno-Gonzalez I, et al.*
(2011) Transmission of Alzheimer Disease and Type 2 Diabetes by a prion mechanism.
Prion 5 Supplement April/May/June ***2011:****14.*

43) *Duran-Aniotz C, Morales R, Estrada L, Urayama A, Morales-Scheihing D, Soto C*
(2012) Induction of amyloid deposition and memory impairments in animal models of Alzheimer disease by blood transfusion.
Prion 6 Supplement April/May/June ***2012:****79.*

44) *Clavaguera F, Bolmont T, Crowther RA, et al.*
(2009) Transmission and spreading of tauopathy in transgenic mouse brain.
Nat Cell Biol ***11:****909-913.*

45) *Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM*
(2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
Neuron ***34:****521-533.*

46) *Mougenot AL, Nicot S, Bencsik A, et al.*
(2011) Prion-like acceleration of a synucleinopathy in a transgenic mouse model.
Neurobiol Aging ***33:****2225-2228.*

47) *Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM*
(2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice.
J Exp Med ***209:****975-986.*

48) *Luk KC, Kehm V, Carroll J, et al.*
(2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.
Science ***338:****949-953.*

49) *Masuda-Suzukake M, Nonaka T, Hosokawa M, et al.*
(2013) Prion-like spreading of pathological alpha-synuclein in brain.
Brain (Epub ahead of print).

50) *Snowdon DA*
(1997) Aging and Alzheimer's disease: lessons from the Nun Study.
Gerontologist ***37:****150-156.*

51) *Snowdon DA*
(2003) Healthy aging and dementia: findings from the Nun Study.
Ann Intern Med ***139:****450-454.*

52) *Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR*
(2007) Healthy ageing in the Nun Study: definition and neuropathologic correlates.
Age Ageing ***36:****650-655.*

53) *Rafalowska J, Barcikowska M, Wen GY, Wisniewski HM*
(1988) Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome.
Acta Neuropathol ***77:****21-25.*

54) *Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S (2010)*
Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life.
Ann Intern Med ***153:****182-193.*

55) *Daviglus ML, Plassman BL, Pirzada A, et al.*
(2011) Risk factors and preventive interventions for Alzheimer disease: state of the science.
Arch Neurol ***68:****1185-1190.*

Literaturhinweise

56) *Kokmen E, Beard CM, O'Brien PC, Kurland LT*
(1996) Epidemiology of dementia in Rochester, Minnesota.
Mayo Clin Proc ***71:****275-282.*

57) *O'Meara ES, Kukull WA, Schellenberg GD, et al.*
(1997) Alzheimer's disease and history of blood transfusion by apolipoprotein-E genotype.
Neuroepidemiology ***16:****86-93.*

58) *Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT*
(1994) Prior blood transfusions and Alzheimer's disease.
Neurology ***44:****1159-1160.*

59) *Darby SC, Kan SW, Spooner RJ, et al.*
(2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
Blood ***110:****815-825.*

60) *Maarouf CL, Daugs ID, Kokjohn TA, et al.*
(2011) Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.
PLoS ONE ***6:****e27291.*

61) *Huang Y, Halliday G*
(2013) Can we clinically diagnose dementia with Lewy bodies yet?
Transl Neurodegener ***2:****4.*

62) *Notari S, Moleres FJ, Hunter SB, et al.*
(2010) Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States.
PLoS ONE ***5:****e8765.*

63) *Roeber S, Grasbon-Frodl EM, Windl O, et al.*
(2008) Evidence for a pathogenic role of different mutations at codon 188 of PRNP.
PLoS ONE ***3:****e2147.*

64) *Anderson VL, Webb WW*
(2011) Transmission electron microscopy characterization of fluorescently labelled amyloid beta 1-40 and alpha-synuclein aggregates.
BMC Biotechnol ***11:****125.*

65) *Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K*
(1995) Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B.
J Biol Chem ***270:****4854-4860.*

66) *Watts JC, Balachandran A, Westaway D*
(2006) The expanding universe of prion diseases.
PLoSPathog ***2:****e26.*